Compare FINV & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | MRVI |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 902.7M |
| IPO Year | 2017 | 2020 |
| Metric | FINV | MRVI |
|---|---|---|
| Price | $4.83 | $6.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.10 | $4.13 |
| AVG Volume (30 Days) | 697.6K | ★ 3.3M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.09% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | N/A | $12.54 |
| Revenue Next Year | $10.58 | $7.87 |
| P/E Ratio | $3.87 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.35 | $1.99 |
| 52 Week High | $10.90 | $6.55 |
| Indicator | FINV | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 48.73 | 68.66 |
| Support Level | $4.67 | $3.27 |
| Resistance Level | $5.23 | N/A |
| Average True Range (ATR) | 0.17 | 0.32 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 49.09 | 67.91 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.